CymaBay Therapeutics Inc. (NASDAQ:CBAY) Director Kurt Von Emster sold 108,876 shares of the stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $7.85, for a total value of $854,676.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Kurt Von Emster also recently made the following trade(s):

  • On Friday, September 29th, Kurt Von Emster sold 211,124 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $8.09, for a total value of $1,707,993.16.

CymaBay Therapeutics Inc. (NASDAQ:CBAY) opened at 8.08 on Friday. The company’s market cap is $353.55 million. The firm has a 50-day moving average price of $6.94 and a 200 day moving average price of $5.47. CymaBay Therapeutics Inc. has a 52 week low of $1.15 and a 52 week high of $8.45.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.06). Analysts expect that CymaBay Therapeutics Inc. will post ($0.82) EPS for the current fiscal year.

WARNING: “Kurt Von Emster Sells 108,876 Shares of CymaBay Therapeutics Inc. (CBAY) Stock” was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/kurt-von-emster-sells-108876-shares-of-cymabay-therapeutics-inc-cbay-stock/1611910.html.

Several research analysts have recently weighed in on CBAY shares. Zacks Investment Research upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, September 18th. Cantor Fitzgerald began coverage on CymaBay Therapeutics in a research note on Tuesday, September 19th. They issued an “overweight” rating and a $16.00 target price for the company. Leerink Swann began coverage on CymaBay Therapeutics in a research note on Wednesday, August 23rd. They issued an “outperform” rating and a $12.00 target price for the company. Ifs Securities restated a “strong-buy” rating on shares of CymaBay Therapeutics in a research note on Monday, July 17th. Finally, Piper Jaffray Companies set a $7.00 target price on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Monday, July 17th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $14.00.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its position in CymaBay Therapeutics by 20.7% in the second quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock worth $5,712,000 after buying an additional 170,126 shares in the last quarter. Boxer Capital LLC purchased a new stake in CymaBay Therapeutics in the first quarter worth about $3,342,000. Renaissance Technologies LLC increased its position in CymaBay Therapeutics by 97.6% in the first quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock worth $997,000 after buying an additional 114,549 shares in the last quarter. Ardsley Advisory Partners increased its position in CymaBay Therapeutics by 66.2% in the second quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after buying an additional 20,000 shares in the last quarter. Finally, Marshall Wace North America L.P. purchased a new stake in CymaBay Therapeutics in the second quarter worth about $242,000. Institutional investors and hedge funds own 25.91% of the company’s stock.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.